Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01

被引：4
|
作者：
Johnson, M. L. [1 ]
Janne, P. A. [2 ]
Goto, Y. [3 ]
Yoh, K. [4 ]
Lee, S-H. [5 ,6 ]
Paz-Ares, L. [7 ]
Besse, B. [8 ]
Novello, S. [9 ]
Hayashi, H. [10 ]
Kim, D-W. [11 ,12 ]
John, T. [13 ]
Kao, S. C-H. [14 ]
Felip, E. [15 ,16 ]
Yang, J. C-H. [17 ]
Reck, M. [18 ]
Dong, Q. [19 ]
Sporchia, A. [19 ]
Sternberg, D. W. [19 ]
Yu, H. A. [20 ]
机构：
[1] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[3] Natl Canc Ctr Hosp, Thorac Oncol Dept, Chuo Ku, Chuo City, Japan
[4] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[5] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[6] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea
[7] Univ Complutense & Ciberonc, Hosp Univ 12 Octubre, Spanish Natl Canc Res Ctr, Madrid, Spain
[8] Univ Paris Saclay, Gustave Roussy, Villejuif, France
[9] Univ Turin, San Luigi Hosp Orbassano, Dept Oncol, Orbassano, Italy
[10] Kindai Univ, Dept Med Oncol, Osaka, Japan
[11] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea
[12] Seoul Natl Univ Hosp, Seoul, South Korea
[13] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[14] Univ Sydney, Sydney Med Sch, Chris OBrien Life House, Sydney, NSW, Australia
[15] Vall dHebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[16] Vall dHebron Inst Oncol, Barcelona, Spain
[17] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan
[18] Airway Res Ctr North, German Ctr Lung Res, LungenClin, Grosshansdorf, Germany
[19] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA
[20] Mem Sloan Kettering Canc Ctr, Dept Med, Med Oncol, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1319MO
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
    Li, B. T.
    Smit, E. F. F.
    Goto, Y.
    Nakagawa, K.
    Udagawa, H.
    Mazieres, J.
    Nagasaka, M.
    Bazhenova, L.
    Saltos, A. N.
    Felip, E.
    Pacheco, J. M.
    Perol, M.
    Paz-Ares, L.
    Saxena, K.
    Shiga, R.
    Cheng, Y.
    Acharyya, S.
    Shahidi, J.
    Planchard, D.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1323 - S1324
  • [42] Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01
    Li, B. T.
    Smit, E. F.
    Goto, Y.
    Nakagawa, K.
    Goto, K.
    Mazieres, J.
    Uprety, D.
    Bazhenova, L.
    Saltos, A.
    Felip, E.
    Pacheco, J.
    Perol, M.
    Paz-Ares, L.
    Saxena, K.
    Shiga, R.
    Cheng, Y.
    Yan, Q.
    Planchard, D.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S995 - S996
  • [43] Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
    Cho, B. C.
    Felip, E.
    Spira, A. I.
    Girard, N.
    Lee, J. S.
    Lee, S. H.
    Ostapenko, Y. V.
    Danchaivijitr, P.
    Liu, B.
    Alip, A.
    Korbenfeld, E. P.
    Dias, J.
    Sun, T.
    Martinez, M.
    Bauml, J. M.
    Shreeve, M.
    Sethi, S.
    Knoblauch, R. E.
    Hayashi, H.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1306 - S1306
  • [44] Dacomitinib (D) Versus Erlotinib (E) in Patients (pt) with EGFR-mutated (mu) Advanced Non-small Cell Lung Cancer (NSCLC): Analyses from a Randomized, Phase 2 Trial
    Ramalingam, S.
    Blackhall, F.
    Rosell, R.
    Mok, T.
    Boyer, M.
    Liang, J.
    O'Connell, J.
    Wang, T.
    Taylor, I.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S203 - S203
  • [45] Prognostic value of neutrophil-to-lymphocyte ratio in advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with a tyrosine-kinase inhibitors: A retrospective analysis in a series of western patients
    Meriggi, Fausto
    Codignola, Claudio
    Beretta, Giordano D.
    Ceresoli, Giovanni Luca
    Caprioli, Alberto
    Scartozzi, Mario
    Fraccon, Anna Paola
    Prochilo, Tiziana
    Ogliosi, Chiara
    Noventa, Silvia
    Libertini, Michela
    Zaniboni, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
    Cho, Byoung Chul
    Ahn, Myung-Ju
    Kang, Jin Hyoung
    Soo, Ross A.
    Reungwetwattana, Thanyanan
    Yang, James Chih-Hsin
    Cicin, Irfan
    Kim, Dong-Wan
    Wu, Yi-Long
    Lu, Shun
    Lee, Ki Hyeong
    Pang, Yong-Kek
    Zimina, Anastasia
    Fong, Chin Heng
    Poddubskaya, Elena
    Sezer, Ahmet
    How, Soon Hin
    Danchaivijitr, Pongwut
    Kim, Yukyung
    Lim, Yeji
    An, Taewon
    Lee, Hana
    Byun, Hae Mi
    Zaric, Bojan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (26) : 4208 - +
  • [47] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Wu, Y-L.
    Tsuboi, M.
    Grohe, C.
    John, T.
    Tarruella, M. Majem
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1549
  • [48] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Tsuboi, M.
    Wu, Y-L.
    Grohe, C.
    John, T.
    Majem Tarruella, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A. L.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1413 - S1414
  • [49] ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome
    Planchard, David
    Cozic, Nathalie
    Wislez, Marie
    Chouaid, Christos
    Curcio, Hubert
    Cousin, Sophie
    Mascaux, Celine
    Cadranel, Jacques
    Geier, Margaux
    Ghigna, Maria Rosa
    Nachabeh, Ghada
    Zwirtes, Ricardo F.
    Chiaverelli, Rachel
    Cheikh-Hussin, Rasha
    Corcos, Noemie
    Mosele, Fernanda
    Andre, Fabrice
    Montagnac, Guillaume
    Pistilli, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
    Eide, Inger Johanne Zwicky
    Grut, Harald
    Helland, Aslaug
    Ekman, Simon
    Sorensen, Jens Benn
    Hansen, Karin Holmskov
    Gronberg, Bjorn Henning
    Cicenas, Saulius
    Koivunen, Jussi Pekka
    Mellemgaard, Anders
    Brustugun, Odd Terje
    ACTA ONCOLOGICA, 2021, 60 (12) : 1565 - 1571
12345